Fosigotifator

Fosigotifator is an experimental small-molecule developed by AbbVie, which is running clinical trials to determine if the drug can treat amyotrophic lateral sclerosis (ALS). A formulation of fosigotifator, as its monosodium phosphate salt mixed with tromethamine, is known as ABBV-CLS-7262. Fosigotifator has been patented by AbbVie and Calico Life Sciences as a prodrug for modulation of the integrated stress response pathway.